Loyal Valley Capital

Loyal Valley Capital is a thematic, research-driven private equity firm.

Business Model:

Revenue: $0

Employees: 0-0

Rankings

Detailed Loyal Valley Capital Information

Geographic Data

Loyal Valley Capital headquarters map

Address: No.1257 Mingyue Road,

City: Pudong

State: shanghai municipality

Zip: 200120

Country: CN

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$1B

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm with strong entrepreneurial culture that invests in middle market companies positioned to benefit from the secular industry transformations in China. With over US$1.6 billion of assets under management, LVC mainly focuses on the following segments: Consumer (TMT, Internet, and Education), Healthcare, and Advanced Manufacturing. Our investment process is characterized by in-depth top-down and bottom-up fundamental research to uncover secular themes and utilize extensive industry mapping to deploy capital in a high conviction and disciplined approach. We pride ourselves as a trusted influential shareholder relentlessly focused on active value creation and accelerating growth via strategic initiatives through our extensive network of business leaders in China. LVC manages capital on behalf of international institutional investors such as sovereign wealth funds, funds of funds, private banks, and family offices, as well as elite entrepreneurs and founders of China’s Fortune 500 enterprises. LVC was founded in 2015 by Andy Lin, an experienced investor and accomplished entrepreneur. He is the founder of China Universal Asset Management (“CUAM”), one of China’s largest equity investor and asset manager with over US$100B in AUM, known for its industry leading research and award-winning investment records.

Contact Phone:

Contact Email:

Announced Date Company Transaction Money Raised
11/2017 Phyplus Series A -
9/2016 Sound Solutions Private Equity Round -
5/2019 NetEase Cloud Music Private Equity Round -
8/2018 Chaodian Culture Angel Round -
12/2016 Xinshixiang Series A 2.7M
10/2018 Linklogis Series C 0
3/2021 Arctic Vision Series B 0
10/2021 Leads Biolabs Series C 0
11/2021 Tripod Preclinical Research Laboratories Venture Round 0
3/2021 Medilink Therapeutics Series A 50M
11/2017 Fortune Finance Venture Round -
5/2018 Immune-Onc Therapeutics Series B -
6/2017 Avary Holding Private Equity Round -
3/2018 Children&s;s House Of Virtues Venture Round -
11/2017 The Child Academy Venture Round -
3/2019 Wajijia Entertainment Series A -
5/2020 Beaver Education Series D -
3/2018 Kaishu Jianggushi Series B 24.7M
2/2018 GeneCast Biotechnology Series C 33M
8/2018 Teligene Series B -
6/2020 JW Therapeutics Series B 0
8/2016 Kangning Hospital Private Equity Round -
9/2017 Gaosi Education Group Series C 83.4M
8/2020 Sinovent Series C 144.7M
11/2019 Akeso Biopharma Series D 150M
11/2018 Immupeutics Medicine Venture Round -
10/2018 ByteDance Equity 3B
2/2021 Regor Therapeutics Series B 0
7/2018 Shanghai Henlius Biotech Venture Round 0
11/2019 Juvenile Get Series A 0
4/2019 Juvenile Get Seed Round -
8/2017 Linklogis Series B 30.1M
3/2021 Xiaoxian Dun Series C -
11/2020 CARsgen Therapeutics Series C 0
6/2017 Studio9 Series A -
5/2019 Allist Pharmaceuticals Series A 173.9M
3/2022 Medilink Therapeutics Series B 70M
7/2017 Pipilu Series B -
6/2020 Heyuan Biotechnology Series C -
12/2017 Sugarman Media Series A -
4/2019 InfiNovo Series A -
11/2016 China Mercy Health Group Series A -
5/2017 Haixue Series C -
5/2020 Pop Mart Private Equity Round 100M
10/2021 Sciwind Biosciences Series C 0
3/2020 Remegen Private Equity Round 0
2/2023 Zhishan Weixin Biotechnology Series A 296.6k
7/2022 Ark Biosciences Series D -
12/2016 Luogic Thinking Series C -
8/2022 Jinyuansheng Series B 147.6M
10/2020 Zhaoke Ophthalmology Pharmaceutical Series B 0
5/2016 Bilibili Series C 199.3M
8/2019 Mahua Fun Age Post-IPO Equity -
4/2020 Mabwell Biotech Series A 0
3/2020 Yatsen Holding Series D 240M
1/2017 ECNUAS Private Equity Round -
6/2022 Frontera Therapeutics Series B 0
5/2018 Sinovent Series A -
2/2020 Kaishu Jianggushi Series C 66M
8/2016 Linklogis Series A 15.1M
2/2022 Chen Xianggui Series B 15.8M
3/2019 Abbisko Therapeutics Series B 42M
2/2018 JW Therapeutics Venture Round -
8/2021 Abogen Biosciences Series C 0
9/2021 Alebund Pharmaceuticals Series B 0
3/2020 Abbisko Therapeutics Series C 70M
11/2016 Shanghai Junshi Biosciences Venture Round -
1/2017 iDreamsky Technology Private Equity Round -
1/2022 Peijie Hotpot Series A 15.8M
3/2018 Didi Private Equity Round 0
8/2017 Rishiji Venture Round -
6/2020 HYGEIA Healthcare Group Private Equity Round -
1/2019 Innocare Private Equity Round 0
7/2020 OBiO Technology Series C 28.5M
9/2018 WeShare Series B 0
3/2019 Jinfuzi Series C -
4/2018 Innomed Series B -
4/2021 EdiGene Series B 61.6M
4/2019 EVE Energy Private Equity Round -
7/2022 Ark Biosciences Series D -
6/2022 Frontera Therapeutics Series B 0
3/2022 Medilink Therapeutics Series B 0
11/2021 Tripod Preclinical Research Laboratories Venture Round 0
10/2021 Sciwind Biosciences Series C 0
10/2021 Leads Biolabs Series C 0
9/2021 Alebund Pharmaceuticals Series B 0
8/2021 Abogen Biosciences Series C 0
4/2021 EdiGene Series B 0
3/2021 Xiaoxian Dun Series C -

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research